StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly & Co. (LLY), Incyte Corporation (INCY) Report Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
February 4, 2019 6:46 AM
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
February 4, 2019 6:45 AM
Lilly (LLY) and Loxo Oncology (LOXO) Announce Expiration of HSR Act Waiting Period for Proposed Transaction
February 1, 2019 6:49 AM
Lilly (LLY) Announces FDA Expanded its ALIMTA Label with Combination of KEYTRUDA and Platinum Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC
January 31, 2019 6:51 AM